PHARMANIAGA GROUP BERHAD

Reply to Bursa Query Reference No: IQL-13012021-00001

In response to the Bursa Malaysia Securities Berhad ("Bursa Securities") query letter ref no. IQL-13012021-00001 dated 13 January 2021 in relation to the Pharmaniaga Berhad's ("Pharmaniaga" or "the Company") announcement dated 12 January 2021, the Board of Directors of Pharmaniaga is pleased to furnish the following additional information:

(Unless otherwise stated, the words and expressions used in this announcement shall have the same meaning as defined in the Company's announcement dated 12 January 2021).

1. **Whether Pharmaniaga Lifescience Sdn Bhd ("PLS") possesses the required expertise, know how and resources to manufacture the Covid-19 vaccine.**

   Answer: Yes, PLS has all the required expertise, know how and resources for fill finish manufacturing of Covid-19 vaccine. PLS has been doing sterile filing & manufacturing of injectable products in vials since 2010 and the facility is approved by the National Pharmaceutical Regulatory Agency and EU GMP certified.

2. **The tentative timeframe to enter into the Local Manufacturing Agreement and the Technology and Know How License Agreement with Sinovac LS.**

   Answer: The Company has initiated negotiation for both agreements and is expected to be executed within one month from the date of signing of the Binding Terms Sheet Agreement.

3. **The risks in relation to the manufacturing of Covid-19 vaccine that PLS may be exposed to.**

   Answer: In terms of virus exposure, there will be none considering the Company will be dealing with killed virus during the manufacturing of the vaccine. However, there might be risk of late delivery from the other party.

4. **To elaborate the manner in which PLS intends to market and distribute the Covid-19 vaccine and whether any contract has been secured to date.**

   Answer: The Company is in the midst of negotiation with the Ministry of Health for the purchase of the vaccine.

5. **To specify the relevant authorities' approvals required for the clinical trial of the Covid-19 vaccine and the manufacturing, distribution and sale of Covid-19 vaccine in Malaysia together with the status of approval, where applicable.**

   Answer: Approval from the National Pharmaceutical Regulatory Agency ("NPRA") is required for the manufacturing and distribution of vaccine in Malaysia. Pre-submission meeting with the NPRA has been completed and the Company will be submitting the vaccine dossier to the NPRA soonest. There shall not be any clinical trials in Malaysia and

the Company will rely on clinical data from China, Indonesia, Turkey and Brazil for registration of vaccine in Malaysia.

6. **The estimated total capital outlay or costs to be incurred and the source of funding for the manufacturing of Covid-19 vaccine.**

   Answer: For refitting of the existing facility to enable manufacturing of Covid-19 vaccine, PLS has budgeted around RM3 million for the purpose.